This is a snip from a press release from CHM in relation to the CDH17 clinical trial data....apparently CHM is working with their media advisers / ASX to get this released on the ASX......
CHM CDH17 Phase 1/2 Trial Update
Chimeric Therapeutics is pleased to provide an update on progress of its CHM CDH17 Phase 1/2 clinical trial to date. Of the three patients dosed at the first dose level of 50 million cells, two patients have achieved Stable Disease, whereby the cancer is neither increasing nor decreasing in extent or severity, with the tumours remaining at approximately the same size with no new tumours appearing. Interestingly, evidence of immune activation of CHM CDH17 CAR-T cells was observed with exceptional expansion and persistence beyond 28 days. Clinical evidence of tumour necrosis was observed, however additional results are required to determine the outcome.
Professor Jennifer Eads of UPenn Oncology and Lead Investigator of the CHM CDH17 trial said:
“These results are encouraging as there are limited treatment options for these patients – as such we look forward to getting more experience with CHM CDH17.”
CHM Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)